Additionally, several preclinical studies in mouse models demonstrated that Fc-dependent depletion of tumor-infiltrating FOXP3+ regulatory T cells (Tregs), which highly express CTLA-4, co-defines the efficacy of anti-CTLA-4 therapy.27 The gene discussed is CTLA4; the disease is neoplasm.